Fig. 5
From: Identification of glutamine as a potential therapeutic target in dry eye disease
The combination therapy alleviated dry eye damage by inhibiting GLS1 to restore glutamine levels, inhibiting downstream inflammation in DED. a Experimental design of inhibition and overexpression of GLS1. b Western blot confirmed the inhibition and overexpression of GLS1. c Inhibition of GLS1 restored the glutamine levels. d, e The RT-qPCR and high-throughput analysis showed an attenuation of inflammatory response by MSC-CM + Tβ4 combination therapy, while overexpression and inhibition of GLS1 reversed/augmented the effects of MSC + Tβ4 on inflammation, respectively. Data are presented as the mean ± SEM, n = 3. f–k Western blotting showed that MSC + Tβ4 down-regulated the IκBα/NF-κB pathway by inhibiting GLS1. Data are presented as the mean ± SEM, n = 4. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
